Fiche publication
Date publication
septembre 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
,
Dr VUITTON Lucine
Tous les auteurs :
Delobeau M, Abdou A, Puzenat E, Deveza E, Biver-Dalle C, Van de Laak A, Roche-Kubler B, Vuitton L, Koch S, Wendling D, Aubin F
Lien Pubmed
Résumé
INTRODUCTION: Although the efficacy of TNF blockers has been demonstrated in hidradenitis suppurativa (HS), many paradoxical effects have also been described with TNF antagonists. We wished to describe patients with adalimumab-induced paradoxical HS. METHODS: This is a retrospective descriptive case series of four patients with adalimumab-induced paradoxical HS. RESULTS: All patients had a good response to TNFa antagonist therapy at the time of HS occurence. The time from TNFa antagonist initiation to HS onset or exacerbation ranged from a few weeks to 24 months. The outcome of HS was variable. Systemic antibiotics were required in all cases to control HS. TNF blockers were continued in 3 cases with a switch to another anti-TNF class in one case. Switch to ustekinumab was prescribed in one patient with SA and Crohn's disease. CONCLUSION: Although the imputability of TNF blockers in paradoxical HS is still debatable, further research and observation are needed to confirm and distinguish patients with genetic and clinical predisposition in the onset or exacerbation of HS during anti-TNF treatment.
Référence
J Dermatolog Treat. 2015 Sep 14:1-10.
